The distinction between sIBM and the other, mostly hereditary vacuolar myopathies, such as myofibrillar myopathies or hereditary inclusion body myopathy with mutations in the glucosamine (UDP-N ...

Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains ...

The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of ...

New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of lead drug ulviprubart and file it for approval for inclusion body ...

An acute necrotising myopathy is a distinct form of uncommon muscle disease characterised by the rapid advancement of ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the ...

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Inclusion Body Myositis - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This report offers in-depth insights into ...

sIBM remains a challenging muscle disease in which inflammatory features coexist with degeneration. Although evidence indicates that there is interplay between the inflammatory mediators ...